- In May 2021, Octapharma USA's investigational new drug (IND) application for a phase three clinical trial on the efficacy and safety of Octagam 10 percent [Immune Globulin Intravenous (Human)] therapy in COVID-19 patients with severe disease progression was authorized by the US Food and Drug Administration (FDA).
